Eighth annual INTERMACS report: Special focus on framing the impact of adverse events

JOURNAL OF HEART AND LUNG TRANSPLANTATION

卷:36

Article

Kirklin, James K.¹  Pagani, Francis D.²  Kormos, Robert L.³  Stevenson, Lynne W.⁴  Blume, Elizabeth D.⁵  Myers, Susan L.¹  Miller, Marissa A.⁶  Baldwin, J. Timothy⁶  Young, James B.⁷  Naftel, David C.¹ 

[1] Univ Alabama Birmingham, Dept Surg, 1900 Univ Blvd, Birmingham, AL 35294 USA

[2] Univ Michigan, Dept Cardiac Surg, Ann Arbor, MI 48109 USA

[3] Univ Pittsburgh, Med Ctr, Heart & Vasc Inst, Dept Cardiothorac Surg, Pittsburgh, PA USA

[4] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA

[5] Boston Childrens Hosp, Dept Pediat, Boston, MA USA

[6] NHLBI, Div Cardiovasc Dis, Adv Technol & Surg Branch, Bldg 10, Bethesda, MD 20892 USA

[7] Cleveland Clin Fdn, Dept Med, Lerner Coll Med, 9500 Euclid Ave, Cleveland, OH 44195 USA

关键词: advanced heart failure;    destination therapy;    INTERMACS;    mechanical support;    ventricular assist device;   

DOI  :  10.1016/j.healun.2017.07.005

来源: Elsevier

【 摘 要 】

BACKGROUND: The Interagency Registry for Mechanically Assisted Circulatory Support (INTER MACS) database now includes >20,000 patients from > 180 hospitals. METHODS: The eighth annual report of INTERMACS updates the first decade of patient enrollment. RESULTS: In the current era, >95% of implants are continuous flow devices. Overall survival continues to remain > 80% at 1 year and 70% at 2 years. Review of major adverse events shows minimal advantage for patients with ambulatory heart failure pre-implant. Stroke, major infection, and continued inotrope requirement during the first 3 months have a major effect on subsequent survival. CONCLUSIONS: Greater application of durable devices to patients with ambulatory heart failure will mandate more effective neutralization or prevention of major adverse events. (C) 2017 International Society for Heart and Lung Transplantation. All rights reserved.

【 授权许可】

Free